Combine is a multicenter, randomized clinical trial that will evaluate combinations of three
interventions for treating alcohol dependence. The goal is to determine whether improvement
in treatment outcomes can be achieved by various combinations of drug and behavioral
interventions. Two of the interventions will consist of pharmacological treatment with
naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent
behavioral therapy including such components as motivational enhancement therapy, cognitive
behavioral therapy, and referral to self-help groups, including AA. All three interventions
will include a component supporting compliance to medications and reduction in drinking.
Phase:
Phase 3
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Lipha Pharmaceuticals National Institute on Alcohol Abuse and Alcoholism (NIAAA)